Alvotech Annual Report: A Simple Guide

I’ve put together this guide to help you understand Alvotech’s performance this year. Instead of digging through hundreds of pages of complex filings, I’ve broken down the key takeaways to help you decide if this company fits your investment goals.

1. What does this company do?

Alvotech is a biotech company that makes "biosimilars." These are high-quality, lower-cost versions of complex, expensive biologic drugs. Because these medicines are difficult to develop and manufacture, Alvotech aims to make life-saving treatments more affordable. They operate globally, with major labs and manufacturing hubs in Iceland, Europe, and the U.S. They use a "partnership-led" model, where they develop the drug and rely on established partners—like Teva Pharmaceuticals—to handle marketing and distribution.

2. Financial Performance: Turning the Corner

For a long time, Alvotech was purely in "spending mode." However, 2025 marked a major milestone: the company reported a profit of $27.9 million. This is a big shift from their losses of $231.9 million in 2024 and $551.7 million in 2023. Revenue hit $350 million, driven by the U.S. launch of Simlandi (AVT02). While they still have a total accumulated loss of $1.4 billion, moving into the black shows their strategy is starting to pay off.

3. Major Wins and Challenges

• Expansion: They received marketing approval for AVT02 and AVT04 in over 30 countries. They also cleared regulatory hurdles for AVT03, AVT05, and AVT06 in Japan, the UK, and the European Economic Area.
• The "Heavy Lifting": Despite the profit, costs remain high. They are investing $185 million in clinical trials this year, alongside building sales teams and protecting their intellectual property.
• The Hurdle: The FDA issued "Complete Response Letters" regarding AVT03, AVT05, and AVT06. These require additional information or facility inspections before the products can be approved for the U.S. market.

4. Financial Health

Alvotech remains a high-stakes investment. They carry significant debt, including $750 million due in 2027. To fund ongoing operations and manage this debt, the company may need to raise additional capital, which could involve issuing more shares and diluting current ownership. Additionally, the company is currently refining its accounting systems for complex licensing deals to ensure full transparency and address identified weaknesses in financial reporting.

5. Key Risks

• Regulatory Roadblocks: Biotech success is never guaranteed. If they cannot satisfy regulators, they cannot sell their products. A single delay can push a product launch back by two years.
• Competition: They face stiff competition from original drug makers and other biosimilar companies, which can drive down prices quickly once a drug hits the market.
• Healthcare Costs: New laws, such as the U.S. Inflation Reduction Act, could limit revenue potential by capping drug prices, which may impact Alvotech’s royalty payments.

6. Future Outlook

Alvotech has successfully transitioned from a research-only company to a commercial one. The next year is about proving they can sustain profitability while managing their $750 million debt load. They have the infrastructure and approvals to scale, but the road remains sensitive to regulatory outcomes and partner performance.

---

Investor Tip: When considering this stock, weigh the company's newfound profitability against the upcoming 2027 debt deadline. Success will likely depend on their ability to resolve FDA inquiries and maintain the momentum of their current product launches.